Company intelligence / Profile preview

Seneque

Ownership: Private
Development stage: Other

Overview

Seneque is conducting the world’s most extensive program of in-human clinical research on nicotinamide mononucleotide (NMN) and other synergistic molecules. Their studies focus on safety, pharmacokinetics, and effects of NMN supplementation in healthy adults. Early results support the safety profile of their lead product but no disease-specific efficacy data has been published yet[1][2][3].

Therapeutic areas: Other
Modalities: Small moleculeNatural molecule (specifically nicotinamide mononucleotide, NMN)
Industry: Biotech

Partnerships

Buck Institute for Research on Aging

Beyond the preview

Go deeper on Seneque.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seneque.

Explore the full profile